Top Ophthalmologists for Intravitreal Injections in Ohio

Dr. Peter Kaiser holds an endowed chair in ophthalmology research at the Cleveland Clinic Cole Eye Institute and has been a principal investigator on many of the clinical trials that established current anti-VEGF injection regimens. His clinic focuses on wet macular degeneration, diabetic retinopathy, and vein occlusion — the three main reasons a patient needs regular injections. He co-led the international classification system for vitreomacular traction and macular hole ¹, which retina specialists across the country still use to decide whether an eye needs injection, surgery, or simple observation.

Dr. Justis Ehlers directs the Campane Center for image-guided surgery at the Cole Eye Institute, where he sees patients with complex retinal disease and uveal melanoma. If you have a retinal vein occlusion and are being told you'll need injections for years rather than months, his work is a reason to ask your doctor about long-term monitoring plans ¹⁴. His lab also helped establish the gene expression patterns that now guide treatment for eye tumors ¹²¹⁵¹⁶.

Dr. Andrew Schachat serves as Vice Chairman for Clinical Affairs and Director of Clinical Research for retinal diseases at Cleveland Clinic, with patient clinics at South Pointe Hospital in Beachwood. He has spent decades shaping how large retina practices run — which means how injection appointments are scheduled, how follow-up imaging is ordered, and how the practice tracks whether your vision is actually improving. Patients referred into the Cole Eye Institute for macular degeneration often end up in a workflow he helped design.

Dr. Elias Traboulsi is a Cleveland Clinic ophthalmologist whose research helped identify several of the genes that cause inherited retinal diseases ⁷⁸¹¹. He is the right starting point if your vision loss runs in your family or if a routine eye exam has turned up an unusual retinal finding that no one can quite explain. His team also contributed to the foundational work on gene therapy for RPE65-related blindness ⁹, the first FDA-approved gene therapy for an inherited eye condition.

Dr. William Dupps is a Cleveland Clinic corneal specialist whose engineering background shaped how ophthalmologists measure the mechanical health of the cornea ². While his primary focus is cornea and refractive surgery rather than retinal injections, patients considering injection therapy often have overlapping corneal issues — past LASIK, dry eye, or keratoconus — and his research on corneal biomechanics ³ and imaging ⁴ informs how retina teams at the same institution screen patients before any eye procedure.

Dr. James Randleman is a Cleveland Clinic refractive surgeon best known for building the ectasia risk score, the standard screening tool used to decide whether a patient is safe for LASIK ¹⁷²⁰. His work matters for injection patients too: older adults who had LASIK decades ago sometimes develop complications that affect how their retina specialist measures the eye and tracks response to treatment. Practices that use his framework tend to screen more carefully before and during injection courses.